Clinical trial
Irinotecan in Treating Patients With Colorectal Cancer
NCT00003843 · California Cancer Consortium, Other · Terminated
Key facts
| NCT number | NCT00003843 |
|---|---|
| Title | Irinotecan in Treating Patients With Colorectal Cancer |
| Official title | UGT1A1 Polymorphism in Patients With Colorectal Cancer Treated With CPT-11 (Irinotecan) |
| Lead sponsor | California Cancer Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Study type | Observational |
| Conditions | Colorectal Cancer |
| Intervention type | Drug, Genetic |
| Interventions | irinotecan hydrochloride, mutation analysis, polymorphism analysis |
| Enrollment | 28 |
| Start date | Oct 1, 1998 |
| Primary completion | Feb 1, 2001 |
| Completion | Feb 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 16, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: